Operating Income - Cutia Therapeutics (HKEX:2487) - Alpha Spread
C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 14.06 HKD -0.28% Market Closed
Market Cap: 4.3B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Cutia Therapeutics
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cutia Therapeutics
Operating Income Peer Comparison

Comparables:
6160
1801
9926
603392
300122

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Operating Income
-ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Income
-ÂĄ1.5B
CAGR 3-Years
-51%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Operating Income
ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ7B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
50%

See Also

What is Cutia Therapeutics's Operating Income?
Operating Income
-2B CNY

Based on the financial report for Dec 31, 2023, Cutia Therapeutics's Operating Income amounts to -2B CNY.

What is Cutia Therapeutics's Operating Income growth rate?
Operating Income CAGR 1Y
-215%

Over the last year, the Operating Income growth was -215%.

Back to Top